The first Integrated Smart Insulin Pen for people with diabetes on MDI

      InPen is the first and only FDA-cleared smart insulin pen available on the market for people on multiple daily injections (MDI). Individuals with diabetes who are currently using InPen can now integrate their continuous glucose monitor (CGM) data from Guardian Connect with insulin dosing data in the InPen smartphone app available for iOS and Android. The InPen which is a reusable, Bluetooth-enabled smart insulin pen automatically captures mealtime doses and keeps track of insulin on board (how much insulin is still active inside your body from the previous bolus). The app tracks insulin doses and glucose levels, includes a bolus calculator, and creates an InPen Insights report that combines glucose and insulin data for further review. This makes diabetes management much easier compared to switching between apps for CGM data and insulin dosing data. The InPen app, now integrated with Guardian Connect, is the second mobile app to combine real-time CGM data and insulin dosing data. Guardian Connect and InPen users can now see, in real-time, their glucose values and trend arrows in the InPen app and the InPen Insights reports.

Read More

Sotagliflozin reduces adverse CVD events in patients with T2D and CKD

      A recent study published in the ‘New England Journal of Medicine’ reported that Sotagliflozin, an inhibitor of sodium–glucose cotransporter 2 (SGLT2), with some SGLT1 inhibitory activity lowers adverse cardiovascular events in high-risk patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) or worsening heart failure. The investigators in the SCORED trial conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (HbA1c ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive Sotagliflozin or placebo.

      The trial enrolled 10,584 individuals with 5292 assigned to the Sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P=0.35).

      The research concluded with the observation that in patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events.

Read More